{"id":"prasugrel-clopidogrel","safety":{"commonSideEffects":[{"rate":"3-5%","effect":"Bleeding (major and minor)"},{"rate":"1-2%","effect":"Dyspnea"},{"rate":"1-2%","effect":"Bradycardia"},{"rate":"1-2%","effect":"Rash"},{"rate":"<0.1%","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":{"chemblId":"CHEMBL1201772","moleculeType":"Small molecule","molecularWeight":"373.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are thienopyridine class antiplatelet agents that irreversibly block the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. Prasugrel is a third-generation thienopyridine with faster onset and greater platelet inhibition compared to clopidogrel. They are used to reduce stent thrombosis and cardiovascular events in acute coronary syndromes and percutaneous coronary intervention.","oneSentence":"Prasugrel and clopidogrel are both P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:02.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina, NSTEMI, STEMI)"},{"name":"Prevention of stent thrombosis following percutaneous coronary intervention"},{"name":"Secondary prevention of atherothrombotic events in patients with acute myocardial infarction"}]},"trialDetails":[{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT05531474","phase":"NA","title":"Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2020-11-02","conditions":"Cardiovascular Complication, Bariatric Surgery Candidate","enrollment":200},{"nctId":"NCT04471870","phase":"","title":"ARCANGELO (itAlian pRospective Study on CANGrELOr)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2020-10-23","conditions":"Acute Coronary Syndrome","enrollment":1005},{"nctId":"NCT04014803","phase":"PHASE4","title":"Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2020-01-13","conditions":"Coronary Artery Disease","enrollment":3500},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT04654052","phase":"PHASE4","title":"VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2021-07-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":634},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT04708587","phase":"NA","title":"Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2021-03-23","conditions":"Chronic Kidney Diseases","enrollment":900},{"nctId":"NCT07032389","phase":"PHASE2","title":"A Polypill for Acute Coronary Syndrome","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-12-05","conditions":"Acute Coronary Syndrome","enrollment":1000},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07025148","phase":"PHASE4","title":"Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-10-01","conditions":"Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)","enrollment":40},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":"Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy","enrollment":1700},{"nctId":"NCT06665919","phase":"NA","title":"The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models","status":"COMPLETED","sponsor":"Vistamedi Ltd.","startDate":"2023-06-15","conditions":"Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis","enrollment":283},{"nctId":"NCT06710262","phase":"","title":"T-TAS® wS Method Comparison","status":"COMPLETED","sponsor":"Hikari Dx, Inc.","startDate":"2024-08-21","conditions":"Antiplatelet Therapy, Healthy Donors, Von Willebrand Disease (VWD)","enrollment":115},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT01777503","phase":"PHASE4","title":"The Elderly ACS II Trial","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2012-11","conditions":"Acute Coronary Syndrome, Coronary Arteriosclerosis, Myocardial Ischemia","enrollment":1457},{"nctId":"NCT05514938","phase":"PHASE2","title":"Polypill in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-30","conditions":"Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease","enrollment":140},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06821191","phase":"PHASE4","title":"Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-03-10","conditions":"Coronary Artery Disease","enrollment":78},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT04100135","phase":"NA","title":"GORE® CARDIOFORM Septal Occluder Migraine Clinical Study","status":"TERMINATED","sponsor":"W.L.Gore & Associates","startDate":"2021-02-05","conditions":"Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale","enrollment":7},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT06613191","phase":"PHASE4","title":"Colonoscopy and Antiplatelet Therapy Trial","status":"NOT_YET_RECRUITING","sponsor":"Ochsner Health System","startDate":"2024-10-01","conditions":"Coronary Arterial Disease (CAD), Peripheral Vascular Disease","enrollment":100},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2017-07-12","conditions":"Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06484647","phase":"","title":"Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation","status":"RECRUITING","sponsor":"San Luigi Gonzaga Hospital","startDate":"2024-06-01","conditions":"Coronary Artery Disease, Ischemic Heart Disease, Chronic Coronary Syndrome","enrollment":382},{"nctId":"NCT03419325","phase":"EARLY_PHASE1","title":"A Genomic Approach for Clopidogrel in Caribbean Hispanics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Puerto Rico","startDate":"2020-09-01","conditions":"Cardiovascular Disease (CVD), Stroke, Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT04609111","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2021-01-29","conditions":"Acute Coronary Syndrome","enrollment":6002},{"nctId":"NCT02317198","phase":"PHASE4","title":"Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2013-06","conditions":"Non-ST-elevation Acute Coronary Syndrome, Unstable Angina, Non-ST-elevation Myocardial Infarction","enrollment":1011},{"nctId":"NCT06400940","phase":"PHASE4","title":"Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2023-08-17","conditions":"Intracranial Aneurysm","enrollment":640},{"nctId":"NCT01556659","phase":"NA","title":"LV Thrombus After Acute AMI: A Randomized Controlled Trial","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2012-03","conditions":"Ventricular Thrombosis Mural Following Myocardial Infarction","enrollment":25},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT05223335","phase":"PHASE4","title":"Clopidogrel Monotherapy in Patients With High Bleeding Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-29","conditions":"Bleeding Complications","enrollment":98},{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88},{"nctId":"NCT01106534","phase":"PHASE4","title":"XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2009-08","conditions":"Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia","enrollment":870},{"nctId":"NCT01765400","phase":"PHASE4","title":"Platelet Inhibition in Patients With Systolic Heart Failure","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2013-05-15","conditions":"Systolic Heart Failure","enrollment":30},{"nctId":"NCT05903976","phase":"PHASE3","title":"De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","startDate":"2023-06-12","conditions":"Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT04237922","phase":"","title":"Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-09-22","conditions":"Antiplatelet","enrollment":43864},{"nctId":"NCT04981041","phase":"PHASE4","title":"Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-12-16","conditions":"Acute Coronary Syndrome, Atrial Fibrillation","enrollment":2334},{"nctId":"NCT05657041","phase":"PHASE2, PHASE3","title":"Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2023-04-26","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":80},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05821062","phase":"","title":"Antiplatelet Therapies in Patients With Depression and Coronary Disease","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2022-04-14","conditions":"Coronary Artery Disease, Depression","enrollment":400},{"nctId":"NCT05122741","phase":"","title":"Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"University of Messina","startDate":"2021-12-01","conditions":"Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular","enrollment":50},{"nctId":"NCT02601157","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01-18","conditions":"Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction","enrollment":2173},{"nctId":"NCT05599152","phase":"","title":"Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel","status":"UNKNOWN","sponsor":"Chan Joon Kim","startDate":"2020-05-21","conditions":"Myocardial Infarction","enrollment":3000},{"nctId":"NCT05359224","phase":"PHASE4","title":"Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-06-13","conditions":"Intracranial Aneurysm","enrollment":406},{"nctId":"NCT03581409","phase":"PHASE4","title":"Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-10-24","conditions":"Aneurysm, Cerebral, Endovascular Procedures","enrollment":198},{"nctId":"NCT01452152","phase":"PHASE4","title":"Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2012-02","conditions":"Cardiovascular Diseases, Acute Coronary Syndrome","enrollment":9},{"nctId":"NCT03672097","phase":"PHASE4","title":"Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company","startDate":"2018-10-16","conditions":"Acute Coronary Syndrome (ACS)","enrollment":204},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT01014624","phase":"PHASE4","title":"Prasugrel/Clopidogrel Maintenance Dose Washout Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-02","conditions":"Coronary Artery Disease","enrollment":56},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT02271022","phase":"","title":"Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-17","conditions":"Acute Coronary Syndromes","enrollment":2000},{"nctId":"NCT02605447","phase":"PHASE4","title":"EVOLVE Short DAPT Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2016-02-16","conditions":"Coronary Artery Disease","enrollment":2009},{"nctId":"NCT03489863","phase":"PHASE4","title":"Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-05-30","conditions":"Coronary Artery Disease","enrollment":14},{"nctId":"NCT01365221","phase":"PHASE4","title":"The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2010-10","conditions":"Acute Coronary Syndrome","enrollment":77},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT02264912","phase":"","title":"The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2008-07","conditions":"Platelet Aggregation Onhibitors","enrollment":2016},{"nctId":"NCT02548611","phase":"PHASE4","title":"Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention","status":"TERMINATED","sponsor":"LMU Klinikum","startDate":"2015-09","conditions":"Angina Pectoris","enrollment":795},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02247128","phase":"PHASE4","title":"Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2014-01","conditions":"Aortic Valve Disease, Myocardial Infarction, Stroke","enrollment":1016},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT01979445","phase":"PHASE2","title":"Cangrelor to Clopidogrel or Prasugrel Transition Study","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2013-12-02","conditions":"Coronary Artery Disease (CAD)","enrollment":15},{"nctId":"NCT03621020","phase":"","title":"Clinical Performance Evaluation of T-TAS 01 PL Chip","status":"COMPLETED","sponsor":"Hikari Dx, Inc.","startDate":"2018-09-01","conditions":"Platelet Dysfunction, Von Willebrand Diseases, Healthy","enrollment":307},{"nctId":"NCT02376283","phase":"PHASE4","title":"P3AMI Antiplatelet Trial","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2015-03-09","conditions":"Heart Attack","enrollment":87},{"nctId":"NCT03815149","phase":"","title":"Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms","status":"UNKNOWN","sponsor":"Gold Coast Hospital and Health Service","startDate":"2019-05-30","conditions":"Intracranial Aneurysm, Cerebral Aneurysm, Subarachnoid Hemorrhage","enrollment":500},{"nctId":"NCT02581280","phase":"","title":"Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-12","conditions":"Cardiac Dysfunction","enrollment":56},{"nctId":"NCT02285751","phase":"PHASE2","title":"High \"on Treatment\" Platelet Reactivity in the Intensive Care Unit","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-11","conditions":"Critical Illness","enrollment":200},{"nctId":"NCT02302508","phase":"PHASE4","title":"Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-09-01","conditions":"Diabetes","enrollment":""},{"nctId":"NCT02030548","phase":"","title":"Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2013-11","conditions":"Acute Coronary Syndrome","enrollment":144},{"nctId":"NCT01761786","phase":"PHASE4","title":"Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)","status":"COMPLETED","sponsor":"Vera HM Deneer","startDate":"2011-06","conditions":"Myocardial Infarction, STEMI","enrollment":2700},{"nctId":"NCT00823212","phase":"PHASE3","title":"The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-01","conditions":"Coronary Artery Disease","enrollment":1530},{"nctId":"NCT01500434","phase":"PHASE3","title":"The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-02","conditions":"Coronary Artery Disease","enrollment":102},{"nctId":"NCT01510327","phase":"PHASE3","title":"PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-10","conditions":"Coronary Artery Disease","enrollment":22},{"nctId":"NCT01959451","phase":"PHASE4","title":"Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial","status":"COMPLETED","sponsor":"LMU Klinikum","startDate":"2013-09","conditions":"Acute Coronary Syndrome","enrollment":2600},{"nctId":"NCT03111420","phase":"NA","title":"Study of AggreGuide A-100 (ADP) Assay","status":"COMPLETED","sponsor":"Aggredyne, Inc.","startDate":"2017-01-09","conditions":"Risk Factor, Cardiovascular, Platelet Dysfunction Due to Drugs","enrollment":280},{"nctId":"NCT01641510","phase":"PHASE3","title":"PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2013-10","conditions":"Acute Coronary Syndromes","enrollment":70},{"nctId":"NCT02118870","phase":"PHASE4","title":"Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent","status":"COMPLETED","sponsor":"Diagram B.V.","startDate":"2014-06-10","conditions":"Acute Coronary Syndrome","enrollment":1500},{"nctId":"NCT03823547","phase":"","title":"Future Optimal Research and Care Evaluation","status":"RECRUITING","sponsor":"J.M. ten Berg","startDate":"2015-01-01","conditions":"Acute Coronary Syndrome, Myocardial Infarction","enrollment":99999},{"nctId":"NCT01260584","phase":"PHASE4","title":"The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-11","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT01930773","phase":"PHASE3","title":"Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2013-03","conditions":"Stable Angina","enrollment":150},{"nctId":"NCT02044146","phase":"PHASE2, PHASE3","title":"A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-09","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":120},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT03184805","phase":"NA","title":"STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2017-06-23","conditions":"Coronary Artery Disease","enrollment":140},{"nctId":"NCT01612884","phase":"PHASE4","title":"Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2011-08","conditions":"Thrombosis, Coronary Artery Disease","enrollment":67},{"nctId":"NCT03469856","phase":"NA","title":"Acetyl Salicylic Elimination Trial: The ASET Pilot Study","status":"UNKNOWN","sponsor":"Pedro A. Lemos","startDate":"2018-02-22","conditions":"Monotherapy After PCI","enrollment":200},{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":"Stable Angina","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"prasugrel / clopidogrel","genericName":"prasugrel / clopidogrel","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prasugrel and clopidogrel are both P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of atherothrombotic events in patients with acute myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}